ADVANCED LUNG NON-SMALL CELL CARCINOMA
Clinical trials for ADVANCED LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis early-phase study tests the safety and best dose of adding minnelide to the standard drug osimertinib for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if the combination can better control tumor growth. About 8 adults with adv…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 03:16 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial tests a new drug (BAY 1895344) combined with standard chemotherapy in people with advanced solid tumors, especially bladder cancer. The goal is to find the safest dose and see how well the combination works. About 74 adults with cancers like lung, bladder, …
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Engineered cord blood cells take on tough lung cancers
Disease control OngoingThis early-phase study tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment uses specially engineered immune cells from umbilical cord blood, designed to better recognize and attack cancer cells…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo aims to halt lung cancer growth
Disease control OngoingThis study tests a new combination of two drugs, osimertinib and telaglenastat, in people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The goal is to find the safest dose and see how well the drugs work together to stop cancer cells from growin…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC